Abstract:The gut microbiota is associated with colorectal cancer (CRC), and identifying harmful or protective microorganisms and their metabolites in patients is of great significance in the diagnosis and treatment of CRC. Herein, the latest reports on the relationship between gut microbiota and metabolites in CRC and the prospects of treating CRC through targeting these metabolites are summarized and discussed. Colorectal cancer (CRC) is the most common cancer of the digestive system with high mortality and morbidity rates. Gut microbiota is found in the intestines, especially the colorectum, and has structured crosstalk interactions with the host that affect several physiological processes. The gut microbiota include CRC‐promoting bacterial species, such as Fusobacterium nucleatum, Escherichia coli, and Bacteroides fragilis, and CRC‐protecting bacterial species, such as Clostridium butyricum, Streptococcus thermophilus, and Lacticaseibacillus paracasei, which along with other microorganisms, such as viruses and fungi, play critical roles in the development of CRC. Different bacterial features are identified in patients with early‐onset CRC, combined with different patterns between fecal and intratumoral microbiota. The gut microbiota may be beneficial in the diagnosis and treatment of CRC; some bacteria may serve as biomarkers while others as regulators of chemotherapy and immunotherapy. Furthermore, metabolites produced by the gut microbiota play essential roles in the crosstalk with CRC cells. Harmful metabolites include some primary bile acids and short‐chain fatty acids, whereas others, including ursodeoxycholic acid and butyrate, are beneficial and impede tumor development and progression. This review focuses on the gut microbiota and its metabolites, and their potential roles in the development, diagnosis, and treatment of CRC.

Gut microbiota and microbiota-derived metabolites in colorectal cancer: enemy or friend

Gut Microbiota-Derived Metabolites in Colorectal Cancer: The Bad and the Challenges

Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer

Gut microbiota in colorectal cancer: mechanisms of action and clinical applications

Gut microbiome in tumorigenesis and therapy of colorectal cancer

Interaction between microbiota and immunity and its implication in colorectal cancer

Role of Gut Microbiota in the Development and Treatment of Colorectal Cancer

Gut microbiota and colorectal cancer: insights into pathogenesis for novel therapeutic strategies

Gut bacteria, host immunity, and colorectal cancer: From pathogenesis to therapy

Gut microbiota in colorectal cancer development and therapy

Effect of gut microbiota in the colorectal cancer and potential target therapy

Gut microbiota modulation: a tool for the management of colorectal cancer

Gut microbiome in gastrointestinal cancer: a friend or foe?

Microbial metabolites in colorectal tumorigenesis and cancer therapy

Gut microbiome: decision-makers in the microenvironment of colorectal cancer

The Roles of Gut Microbiota Metabolites in the Occurrence and Development of Colorectal Cancer: Multiple Insights for Potential Clinical Applications

Exploring the Gut Microbiome’s Role in Colorectal Cancer: Diagnostic and Prognostic Implications

Alterations in the Gut Microbiota and Their Metabolites in Colorectal Cancer: Recent Progress and Future Prospects

Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer

The gut microbiota, bacterial metabolites and colorectal cancer

Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities